Literature DB >> 28375940

Electrophysiological Studies to Detect Peripheral Neuropathy in Children Treated With Vincristine.

Marko Kavcic1, Blaz Koritnik, Matevz Krzan, Orjana Velikonja, Tomaz Prelog, Milica Stefanovic, Maruša Debeljak, Janez Jazbec.   

Abstract

Patients treated with vincristine predictably develop peripheral neuropathy. The aim of our study was to investigate the pattern of vincristine-induced neuropathy in children by nerve conduction studies and somatosensory-evoked potentials (SSEPs). We included data from 39 children who received vincristine for various pediatric malignancies, and we performed initial and follow-up (after a minimum of 4 doses of vincristine 1.5 mg/m) conduction studies in 27 patients and SSEPs studies in 34 patients. On follow-up the most prevalent symptoms were paresthesias (44%) and constipation (22%), and the most common neurological sign was impaired myotatic reflexes (89%). Performing nerve conduction studies we found that significant reductions were measured for distal amplitudes, distal latencies were prolonged, and conduction velocities were relatively preserved. The most pronounced differences in amplitudes and distal latencies were measured in the peroneal nerves. Changes of SSEPs studies were subtle. Vincristine-induced neuropathy presents with primary axonal involvement and is more pronounced on motor neurons. We found a trend between higher age and higher dose and the degree of neuropathy in our group of patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28375940     DOI: 10.1097/MPH.0000000000000825

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  8 in total

Review 1.  Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.

Authors:  Paola Jimenez; Claudio Tatsui; Aaron Jessop; Sonali Thosani; Camilo Jimenez
Journal:  Curr Oncol Rep       Date:  2017-10-28       Impact factor: 5.075

Review 2.  Peripheral neuropathy in children and adolescents treated for cancer.

Authors:  Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness
Journal:  Lancet Child Adolesc Health       Date:  2018-09-01

3.  Update on Toxic Neuropathies.

Authors:  Jannik Peters; Nathan P Staff
Journal:  Curr Treat Options Neurol       Date:  2022-04-06       Impact factor: 3.972

4.  Centrosomal protein72 rs924607 and vincristine-induced neuropathy in pediatric acute lymphocytic leukemia: meta-analysis.

Authors:  Aida Zečkanović; Janez Jazbec; Marko Kavčič
Journal:  Future Sci OA       Date:  2020-05-27

5.  Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.

Authors:  Alex Molassiotis; Hui Lin Cheng; Violeta Lopez; Joseph S K Au; Alexandre Chan; Aishwarya Bandla; K T Leung; Y C Li; K H Wong; Lorna K P Suen; Choi Wan Chan; Janelle Yorke; Carole Farrell; Raghav Sundar
Journal:  BMC Cancer       Date:  2019-02-08       Impact factor: 4.430

6.  Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.

Authors:  Marie Lindhard Madsen; Hanne Due; Niels Ejskjær; Paw Jensen; Jakob Madsen; Karen Dybkær
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-18       Impact factor: 3.333

7.  Polyneuropathy in Acute Lymphoblastic Leukemia Long-Term Survivors: Clinical and Electrophysiological Characteristics With the Impact of Radiotherapy.

Authors:  Slawomir Kroczka; Konrad Stepien; Izabela Witek-Motyl; Tomasz Klekawka; Eryk Kapusta; Agnieszka Biedron; Pawel Skorek; Hanna Twardowska; Klaudia Stasik; Szymon Skoczen
Journal:  Front Pediatr       Date:  2021-02-09       Impact factor: 3.418

Review 8.  Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor.

Authors:  Qing-Yan Yang; Ya-Hui Hu; Hong-Li Guo; Ying Xia; Yong Zhang; Wei-Rong Fang; Yun-Man Li; Jing Xu; Feng Chen; Yong-Ren Wang; Teng-Fei Wang
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.